Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: mackiewicz j. Future Oncol. 2024 May;20(15):959-968. doi: 10.2217/fon-2023-0977. Epub 2024 Feb 23. Future Oncol. 2024. PMID: 38390818 Review.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: mackiewicz j. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Nat Med. 2023. PMID: 37845511 Free PMC article. Clinical Trial.
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: mackiewicz j. Nat Med. 2024 Feb;30(2):607. doi: 10.1038/s41591-023-02661-5. Nat Med. 2024. PMID: 37923838 Free PMC article. No abstract available.
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: mackiewicz j. Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02775-w. Nat Med. 2024. PMID: 38177857 Free PMC article. No abstract available.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. Among authors: mackiewicz j. J Clin Oncol. 2024 May 10;42(14):1619-1624. doi: 10.1200/JCO.23.02355. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452313 Free PMC article. Clinical Trial.
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Rolski J, Sałek-Zań A, Gajewska-Wicher K, Drosik-Kwaśniewska A, Rogala P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: mackiewicz j. Immunotherapy. 2021 Mar;13(4):297-307. doi: 10.2217/imt-2020-0217. Epub 2020 Dec 23. Immunotherapy. 2021. PMID: 33353420
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Piejko K, Cybulska-Stopa B, Ziętek M, Dziura R, Galus Ł, Kempa-Kamińska N, Ziółkowska B, Rutkowska E, Kopciński T, Kubiatowski T, Bal W, Suwiński R, Mackiewicz J, Kamińska-Winciorek G, Czarnecka AM, Rutkowski P. Piejko K, et al. Among authors: mackiewicz j. Target Oncol. 2023 Mar;18(2):235-245. doi: 10.1007/s11523-023-00954-w. Epub 2023 Mar 11. Target Oncol. 2023. PMID: 36906728 Free PMC article.
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Gogas H, et al. Among authors: mackiewicz j. Ann Oncol. 2021 Mar;32(3):384-394. doi: 10.1016/j.annonc.2020.12.004. Epub 2020 Dec 10. Ann Oncol. 2021. PMID: 33309774 Free article. Clinical Trial.
Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study.
Słowińska M, Dudzisz-Śledź M, Sobczuk P, Łasińska I, Pietruszka A, Cybulska-Stopa B, Kowalczyk A, Świtaj T, Czarnecka I, Koseła-Paterczyk H, Rogala P, Paluchowska E, Składowski K, Mackiewicz J, Rutkowski P, Owczarek W. Słowińska M, et al. Among authors: mackiewicz j. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1219-1228. doi: 10.1111/jdv.18070. Epub 2022 Apr 5. J Eur Acad Dermatol Venereol. 2022. PMID: 35279879 Free PMC article.
232 results